AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adults

AstraZeneca's registry activity for the period centers on one completed early-phase study and one recruiting observational study, both last updated on September 28, 2026.

• A Phase I, randomized, open-label crossover study assessed how a fixed-dose combination tablet of laroprovstat and ezetimibe compares with the individual tablets in healthy adults, including a food-effect comparison.¹ The study, which reached study completion on 2026-09-06¹, enrolled 18 participants (actual)¹.
• The PICAROS study is a multicenter non-interventional study of patients with chronic lymphocytic leukemia treated with first-line acalabrutinib under routine clinical practice in Spain², with an overall status of recruiting². The study, sponsored by AstraZeneca, has an estimated enrollment of 315 participants² and its primary outcome is the proportion of patients on acalabrutinib therapy at 24 months after treatment initiation in cohort 1².